Efficacy and Safety of Donepezil for Lewy Body Dementia: A Systematic Review and Meta‐Analysis
This meta-analysis of randomized controlled trials did not find significant differences in cognitive function (MMSE) or behavioral symptoms (NPI-10, NPI-2, ZBI) between donepezil (3, 5, and 10 mg/day) and placebo in patients with LBD.
Authors
- M. M. Fouad
- Youssef A. Ismail (ORCID: https://orcid.org/0000-0003-0003-5492)
- Nadeen A Nagy
- Nada A. Hamdan
- Noreen M. El‐Bayaa
Institutions
- Port Said University (EG)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103155
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00